학술논문

Opioid, sedative, preadmission medication and iatrogenic withdrawal risk in UK adult critically ill patients: a point prevalence study
Document Type
Clinical report
Source
International Journal of Clinical Pharmacy. October 2023, Vol. 45 Issue 5, p1167, 9 p.
Subject
Medical research
Medicine, Experimental
Antidepressants
Alfentanil
Dexmedetomidine
Drugs
Medical errors
Adults
Remifentanil
Hospital patients
Health
Language
English
ISSN
2210-7703
Abstract
Background Iatrogenic withdrawal syndrome, after exposure medication known to cause withdrawal is recognised, yet under described in adult intensive care. Aim To investigate, opioid, sedation, and preadmission medication practice in critically ill adults with focus on aspects associated with iatrogenic withdrawal syndrome. Method One-day point prevalence study in UK intensive care units (ICUs). We collected ICU admission medication and/or substances with withdrawal potential, sedation policy, opioid and sedative use, dose, and duration. Results Thirty-seven from 39 participating ICUs contributed data from 386 patients. The prevalence rate for parenteral opioid and sedative medication was 56.1% (212 patients). Twenty-three ICUs (59%) had no sedation/analgesia policy, and no ICUs screened for iatrogenic withdrawal. Patient admission medications with withdrawal-potential included antidepressants or antipsychotics (43, 20.3%) and nicotine (41, 19.3%). Of 212 patients, 202 (95.3%) received opioids, 163 (76.9%) sedatives and 153 (72.2%) both. Two hundred and two (95.3%) patients received opioids: 167 (82.7%) by continuous infusions and 90 (44.6%) patients for longer than 96-h. One hundred and sixty-three (76.9%) patients received sedatives: 157 (77.7%) by continuous infusions and 74 (45.4%) patients for longer than 96-h. Conclusion Opioid sedative and admission medication with iatrogenic withdrawal syndrome potential prevalence rates were high, and a high proportion of ICUs had no sedative/analgesic policies. Nearly half of patients received continuous opioids and sedatives for longer than 96-h placing them at high risk of iatrogenic withdrawal. No participating unit reported using a validated tool for iatrogenic withdrawal assessment.
Author(s): Rebekah Eadie [sup.1] [sup.2], Cathrine A. McKenzie [sup.3] [sup.4] [sup.5], Daniel Hadfield [sup.5] [sup.6], Nicola J. Kalk [sup.5] [sup.7], Scott Bolesta [sup.8], Martin Dempster [sup.1], Daniel F. McAuley [sup.1], [...]